Category Archives: Platelet Rich Plasma Injections


Stem Cell Clinic > Platelet Rich Plasma Injections

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

By Platelet Rich Plasma Injections

PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain.

Excerpt from:
Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

By Platelet Rich Plasma Injections

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta), Sutro’s Tubulin FR?-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer and other FR? expressing cancers.

More here:
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

By Platelet Rich Plasma Injections

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission

Read more here:
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening

By Platelet Rich Plasma Injections

VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple molecular targets. This milestone further expands the capability to establish QUANTRO’s innovative QUANTROseq® platform as a pioneering technology in the fight against diseases driven by transcriptional dysregulation, such as cancer and inflammation indications.

Read more:
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

By Platelet Rich Plasma Injections

GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.

Continue reading here:
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Quris-AI’s Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation

By Platelet Rich Plasma Injections

Quris-AI to Provide Safety Assessments for Small Molecule Drug Candidates Before Initiating Clinical Trials Quris-AI to Provide Safety Assessments for Small Molecule Drug Candidates Before Initiating Clinical Trials

See original here:
Quris-AI's Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

By Platelet Rich Plasma Injections

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET.

Original post:
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

←